When evaluating consumer products for safety, one must consider the heterogeneity of the population that might use those products, including the potential for different sensitivity based on factors such as age, gender, and genetics. For both systemic endpoints and allergic contact dermatitis (ACD), quantitative safety evaluations typically include a default 10-fold uncertainty/assessment factor to account for inter-individual variability. While this factor is intended to include age, the adequacy of the default 10-fold factor has been questioned for infants, for whom a precautionary assumption is often made that they are more sensitive. In-depth evaluations of the adequacy of the 10-fold factor have been published for systemic endpoints, but relatively little has been published to substantiate this for ACD. This paper reviews the state of the science regarding the etiology of ACD and factors that suggest an overall decreased sensitivity associated with early life exposures, thus confirming the sufficiency of the 10-fold inter-individual factor to provide protection for children and infants. While it remains prudent for all age groups to avoid contact with sensitizers, it is concluded that the quantitative methods used in safety evaluation to prevent the induction of skin sensitization are protective for infants, including neonates and premature infants.
Introduction
When evaluating consumer products for safety, one must consider the heterogeneity of the population that might use those products. This includes the potential for higher or lower exposure for all routes as well as the potential for different sensitivity based on factors such as age, gender, and genetics. For systemic endpoints, quantitative safety evaluations typically include a default 10-fold uncertainty factor (UF) to account for inter-individual variability. Felter et al. (2015) confirmed the adequacy of this default UF for systemic endpoints when assessing safety for infants and children as long as the exposure assessment adequately reflects these life stages. This includes age-specific physiological parameters as well as habits and practices. Similarly, for allergic contact dermatitis (ACD), initial evaluations concluded that a 10-fold default UF provides adequate protection for all ages, including infants and children (Felter et al., 2002; Nikolovski et al., 2008) . However, there have also been suggestions that infant skin exhibits a greater tendency to develop irritant/allergic contact dermatitis compared to adult skin (Nikolovski et al., ý2008) . In a general review of quantitative risk assessment methods for skin sensitization, Basketter and Safford (2016) reconfirmed that the default 10-fold factor, now referred to as a "Sensitization Assessment Factor" (SAF), provides adequate protection for infants and children. A submission to the EU Scientific Committee on Consumer Safety (SCCS) similarly concludes that "the experimental evidence appears to show that young children are less easy to sensitise, so that a risk assessment for adults is conservative for children" (IDEA, 2016) . This conclusion was cited by the SCCS in its 2018 Final Opinion on Skin Sensitization Quantitative Risk Assessment for Fragrance Ingredients (QRA2), although it is recognized that the SCCS still raises questions about the scientific basis for the inter-individual SAF default value of 10-fold (SCCS, 2018) . Questions in the literature have persisted especially for infants, for whom a precautionary assumption is often made that they are more sensitive. This paper reviews the state of the science regarding the etiology of ACD and the sufficiency of the 10-fold inter-individual SAF specifically to provide protection for children and infants, including those under 6 months old.
allergy'. The development of ACD following dermal exposure to an allergen is a two-stage process: induction and elicitation. In the first stage (induction), a hapten reacts with proteins in the epidermis to form adducts that are recognized by antigen-presenting dendritic immune cells present in the skin (e.g., Langerhans cells) as foreign, and ultimately lead to a proliferation of T cells. Subsequent exposure to the same hapten leads to recruitment of activated T cells and other inflammatory mediators (elicitation), which ultimately results in the adverse skin reaction. While the basic biological processes leading to skin sensitization are generally understood, it is also increasingly recognized to be complex, with multiple roles for different types of immune cells including subsets of both T cells and B cells as well as cutaneous dendritic cells (reviewed in Honda et al., 2013) .
ACD is a common skin condition and can affect a significant fraction of the general population. Based on a study by Diepgen et al. (2016) , 27% of the general European population had at least one positive reaction to an allergen of the European diagnostic patch test baseline series used by dermatologists, with a significantly higher prevalence in women than in men. Over the last several years, there has been an increased awareness of ACD in children in addition to adults (e.g., Bonchak et al., 2018; Simonsen et al., 2011; Seidenari et al., 2005; Zug et al., 2014; Admani and Jacob, 2014) . Older children up to the age of 18 years have been widely studied. In general, their ability to react to allergens, and the prevalence of positive patch tests is in line with those of adults. Recent data on > 2200 adolescents in Sweden (Lagrelius et al., 2016) had 15.3% with at least one positive patch test reaction, with a prevalence of 0-2% for each allergen, except for nickel which was much higher (9%). Fragrance mix I was the second most common allergen in this study.
Several very comprehensive reviews of all patch test data with infants and children between the age of 0 and 18 years (Bonitsis et al., 2011; Simonsen et al., 2011; Admani and Jacob, 2014; Zug et al., 2014) showed that they can also become sensitized. An increase in sensitization rate through childhood to adolescence and adulthood is generally seen, with some exceptions published (Belloni Fortina et al., 2015) . This is to be expected, as exposure to sensitizers likely increases with age. While these data are not instructive with regard to the relative susceptibility of infants and children compared to adults, it is still helpful to understand the prevalence of sensitization in these age groups. Patch testing remains the gold standard diagnostic tool to determine prevalence of contact allergy, for both adults and children, but interpretation of the results in children and comparison with patch test data on adults are not straightforward. Patch testing in older children (∼12 and older) follows usually the same procedure as for adults, using the same set of allergens from a patch testing tray (de Waard-van der Spek et al., 2013) . For younger children and especially for infants, patch testing is not yet as standardized and when it is done, adjustments might have been made on the choice of individual allergens or patch testing conditions, which makes the direct comparison to standard patch testing in adults difficult (Militello et al., 2006; Brod et al., 2015) .
To understand better which allergens are responsible for ACD in children, Bonitsis et al. (2011) conducted a systemic review and metaanalysis of 49 studies published between 1963 and 2010. Each study included at least 100 children, with most including a broad range of ages from infants up to 20 years old adolescents. The top 5 allergens identified were nickel sulfate, ammonium persulfate, gold sodium thiosulfate, thimerosal, and p-toluenediamine. It is noted that none of these are used in personal care products to which infants would be exposed. With the exception of thimerosal (present in vaccines), the top allergens likely were identified in older children and teenagers in whom reactions resulted from exposure to jewelry and fasteners (nickel, gold); hair bleaching and/or dyeing (ammonium persulfate, p-toluenediamine). Admani and Jacob (2014) also reviewed the patch testing data globally between 2004 and 2013 and reported a similar rate of contact sensitization for adults and children though with differing allergen frequencies. It is noted that a high positive patch test rate as seen for one allergen (e.g., thimerosal) does not necessarily correlate with a high clinical relevance; in the case of thimerosal, exposure occurs only with vaccines.
There are a number of allergens that were found across most pediatric age groups namely: nickel or chromium salts, Myroxylon pereirae (Balsam of Peru), cobalt chloride, neomycin sulfate, fragrance mix, gold sodium thiosulfate, thimerosal, and formaldehyde, but also paraphenylenediamine (PPD) and toluene-2,5-diamine (PTD), two hair dye actives. While overall the same allergens seem to appear in the top ranks in all studies, there is a change of the ranking order depending on the age of the children tested. For example, PPD or PTD or fragrance mix 1 has a higher frequency in older children, compared to younger ones (Belloni Fortina et al., 2015) . These changes can be most likely attributed to different age dependent product usages and exposure to these allergens. When reviewing ACD in children one needs to consider the different exposures of infants and children compared to adults or over their childhood due to the variation in behavior and activities. This can impact the frequencies of positive patch tests detected and the relevant allergens found (reviewed in Brod et al., 2015) . In addition, there also seems to be a development of a change of allergens over the years (Vongyer and Green, 2015) . Methylchloro-isothiazolinone/methylisothiazolinone (MCI/MI) was found more often in more recent studies (Smith et al., 2016) . This could be mainly related to a change in exposure towards those chemicals.
In contrast to the information available on children and adults, little information is available specifically on the prevalence of sensitization in infants. The occurrence of ACD in children ages 6 months to 5 years was studied by Bruckner et al. (2000) . Ninety-five asymptomatic children were patch tested using the "Thin-Layer Rapid Use Epicutaneous Patch Test" system, which contains 24 allergens. Of the 85 children who completed the study, 20 were found to react to at least one allergen; 16 had one positive reaction, and four had two positive reactions. Nickel and thimerosal were by far the most common allergens, with a total of 11 children reacting to nickel and eight reacting to thimerosal. Two children had positive reactions to Kathon CG (n = 2), and one child each reacted to neomycin, cobalt, and p-tert-butylphenol. In infants up to 18 months old (n = 9), the only responses seen were to nickel (n = 5), thimerosal (n = 1), cobalt (n = 1) and Kathon CG (n = 2). In the two subjects who were 6 months old, responses were found only to nickel and thimerosal. This is in line with other studies by Weston et al. (1986) and Barros et al. (1991) and is a general reflection of sensitization rates for that age group. Johnke et al. (2004) evaluated > 500 children below 18 months for nickel and fragrance allergy, with positive findings for Ni but not for fragrance mix, which could be related to limited exposure to fragrance allergens. Smith et al. (2016) also presented the patch test data by children's age group with a lower number of cases in the < 5 years age groups.
Safety assessment approach for the induction of skin sensitization
Dose-response relationships have been demonstrated for the induction of skin sensitization in humans (Friedmann et al., 1983 (Friedmann et al., , 1990 and, more extensively, in the murine local lymph node assay (LLNA) (Gerberick et al., 2005) . As such, it is possible to identify a threshold exposure level below which the induction of sensitization is not expected to occur. This threshold exposure level, designated as the No Expected Sensitization Induction Level (NESIL), serves as the foundation for the quantitative risk assessment (QRA) approach for the induction of skin sensitization Gerberick et al., 2001) . QRA for skin sensitization mirrors the four-step process of the National Academy of Science (NAS, 1983) risk assessment paradigm: hazard identification; dose-response assessment; exposure assessment; and risk characterization. The NESIL is comparable to the NOAEL (No Observed Adverse Effect Level) used for evaluating systemic toxicity endpoints. While NOAELs are typically expressed in mg/kg body weight, the dose metric for the NESIL is ug/cm 2 . It has been demonstrated that the dose of chemical per unit area of skin, rather than the concentration of chemical expressed as percentage, is the key metric in the induction of skin sensitization (reviewed by Kimber et al., 2008) . Skin penetration is not considered in the exposure calculation when conducting a standard QRA for skin sensitization. Instead, conservative assumptions are made. For 'leave-on' products it is assumed that 100% of the amount applied to the skin surface (dose) is bioavailable. Exposure calculations for 'rinse-off' products include a retention factor which reflects the amount of product remaining on the skin following the rinse (Gerberick et al., 2001 ). All remaining product on the skin is then considered to be bioavailable and is counted towards exposure. Exposure from articles such as diapers and wipes can be more challenging to assess and require analytical data often in conjunction with the use of default assumptions regarding the potential for a substance to transfer from the article to the infant's skin (e.g., Dey et al., 2016; Hossain et al., 2015) .
In general, risk assessment uncertainty factors (UF) are applied to a NOAEL to account for areas of extrapolation from the experimental conditions of the NOAEL-defining study to human exposure conditions. In skin sensitization QRA, this necessary extrapolation is achieved by the application of SAFs to the NESIL Gerberick et al., 2001) . The scientific evidence to support the areas of uncertainty accounted for by the SAFs has been reviewed, originally by Felter et al. (2002) and more recently by Basketter and Safford (2016) . The four basic areas currently accounted for with SAFs are inter-individual variability, product considerations, frequency and duration of exposure, and skin condition. The SAFs for each of these are multiplied together in the same way that uncertainty factors are used for other thresholdbased effects; this ensures an additional degree of conservatism.
The 10-fold SAF for inter-individual variability considers the following variations within the human population which may contribute to the acquisition of skin sensitization: age, gender, ethnicity, existing disease states, and genetic factors. Based on the information available concerning the relationship between the previously stated areas of variation and the susceptibility to the induction of skin sensitization, Basketter and Safford concluded that an especially sensitive subpopulation could not be identified beyond those already considered and accounted for by the 10-fold inter-individual SAF. It is noted that a NESIL is a human threshold that already incorporates a measure of human variability. For example, human patch studies (e.g., Human Repeat Insult Patch Test) that are used as the basis for a NESIL are generally conducted in 100 people, such that much of human variability is captured. However, these studies are conducted only in adults and do not provide empirical data in children or infants; this is the focus of this manuscript.
The product considerations SAF takes into consideration the role of the product formulation or matrix. There is some evidence to suggest that the composition of the product chassis which contains the allergen may have an impact on the induction of sensitization (Basketter and Safford, 2016) . For most product types, this SAF is assigned a value of 1, but for products with minimal direct skin contact such as candles, a value of 0.3 is more appropriate. In cases where the product formulation (or combination of a formulated product with a device) results in enhanced skin penetration, then a product SAF of 3 may be used.
The frequency/duration SAF accounts for the fact that many products are used once or multiple times daily over a course of time which may span years. The frequency/duration was assigned a pragmatic value of 3.
The skin condition SAF accounts for exposures to skin sites which may be compromised or inflamed or skin sites such as the hands which may be exposed more often to irritating chemicals (Basketter and Safford, 2016) . A value of 1, 3 or 10 is assigned to this SAF. For example, the scalp has a skin condition SAF of 1 while the ano-genital region is assigned a 10. For products such as diapers and baby wipes the skin condition SAF is 10, in recognition of the potential for compromised skin.
Intra-human variability: infants and premature infants

Exposure as a determinant of susceptibility
At the center of any safety assessment is a quantitative evaluation of exposure. It is well-recognized that infants and children can experience greater exposure (per kg body weight) than adults because of their small body size; in other cases, their exposure can be substantially less because of different habits and practices. Because they are actively growing, infants and children have a higher intake of food and water, when considered on a mg/kg bw/day basis. The question of higher exposure has also been highlighted in Notes of Guidance (NoG) for the Testing of Cosmetic Ingredients and their Safety Evaluation issued by the EU Scientific Committee on Consumer Safety (SCCS, 2016). Specifically, the SCCS acknowledged the potential for infants and children to have higher exposure to some personal care products because of their greater Skin Surface Area to Body Weight ratio (SSA/BW) compared to adults. The SCCS cited data from Renwick (1998) suggesting the greatest difference for a newborn to be 2.3-fold, and that this quickly drops off such that it is only 1.8-fold by 6 months; 1.6-fold by 1 year; and 1.5-fold by 5 years. The SCCS goes on to state that the maximum factor of 2.3 is covered by the default uncertainty factor applied to account for human variability.
Importantly, while systemic exposure could be higher for infants and young children based on their higher SSA/BW ratio, this is not generally true for exposure to the skin. For many personal care products applied to the skin (e.g., body lotion, shampoo, soap), it is likely that exposure in units of ug per square centimeter of skin (the relevant dose metric for sensitization; see Section 3) is similar across age groups. Ideally, habits and practices data should be based on actual exposure within the appropriate age groups such that, for personal care products intended to be used with infants and children, extrapolation of exposure data from adults is not needed and SSA/BW difference is not a factor for either skin or systemic exposure calculations. For products designed specifically for use with infants (e.g., diaper cream), it is particularly important that the exposure assessment reflect the actual usage in that age group. This is an important aspect of the safety evaluation performed by manufacturers of personal care products, although there remains a need for more published data on exposure to infants and children. To help address this data gap, Cosmetics Europe initiated a project in 2018 to generate reliable exposure data for personal care products amongst infants and toddlers in Europe aged 0-3 years of age, similar to previous exposure studies published for adults (Hall et al., 2007 (Hall et al., , 2011 .
Another factor that can impact exposure through the skin relates to the potential for a compromised skin barrier. Although the skin of neonates continues to undergo a process of adaptation and maturation over many months, it is generally recognized to have competent barrier properties at birth (Hoeger and Enzmann, 2002; Fluhr et al., 2012; Ludriksone et al., 2014) . Full term infants have a well-developed epidermis similar to that of adults with a comparable number of keratinocyte layers and lipid barriers. When conducting an exposure assessment for substances in contact with the skin, differences between the skin of healthy full-term infants and that of older children or adults are sufficiently minor such that current methods for quantifying dermal absorption are considered appropriate for all age groups. However, as discussed earlier, it is also recognized that there is a potential for increased dermal absorption in the ano-genital region and skin under diapers, which has the potential to be compromised by diaper rash. In recognition of this, quantitative safety assessments for products used in these areas are assigned the most conservative default "skin condition SAF" of 10-fold. Similarly, for infants born prematurely, the barrier properties of the skin are not yet fully developed and the potential for greater dermal penetration of substances in contact with the skin must be considered (Afsar, 2009) . That said, a default assumption of 100% dermal penetration is commonly made when conducting safety assessments for infants, such that any differences in skin barrier properties are no longer a factor.
Inherent susceptibility: development of the immune system
While the potential for infants to experience ACD is recognized, young infants are likely to be less susceptible than older children and adults because the immaturity of the immune system is associated with a diminished capacity to mount an allergic response. This is supported by what is known about the development of the immune system and is supported by limited clinical data (e.g., Cassimos et al., 1980) , described in Section 5.
The development of the immune system in utero and in the neonatal period has been described (Ygberg and Nilsson, 2011; Simon et al., 2015; Rechavi et al., 2015) . While its origins are found early in fetal life, the immune system of the fetus is not very reactive; this is critical for survival as the fetus must not react to maternal alloantigens. Even by the time of birth, the development of the immune system is far from complete, and protection of the infant is largely provided by maternal antibodies that were passed to the infant in utero (Niewiesk, 2014) . Maturation of the immune system occurs over a period of years with the first months of life being especially important to ensure protection of the infant as maternal antibodies passed in utero start to decline (Niewiesk, 2014; Rechavi et al., 2015) . The immaturity of the immune system of neonates and young infants has consequences that can render the infant more susceptible to infections, and also less able to mount an antibody response to immunization (reviewed in Hayward, 1983; Siegrist, 2001; Demirjian and Levy, 2009; Debock et al., 2013) . Maternal antibodies passed to the infant have the potential to negatively impact antibody generation after vaccination. For these reasons, it is generally recommended by the Centers for Disease Control (CDC, 2018) that initial vaccines not be given until an infant is two months old. One exception is the Hepatitis B vaccine which is recommended to be given at birth, but as noted by Siegrist (2001) , the antibody response rate is relatively low and additional doses are necessary for an infant to be protected. Indeed, many vaccines are given in several doses that are spaced throughout the first 24 months of life.
While there can be negative health consequences associated with the immaturity of the immune system in young infants, this immaturity also renders the young infant less susceptible to adverse effects such as ACD that are mediated through an immune response. Less is published about adaptive immune responses like ACD, but there is sufficient reason to believe that maturation will somewhat parallel that of the innate immune responses. This is supported by the existing literature of preclinical and clinical evaluation of the potential for delayed hypersensitivity reactions in early life, described in Section 5.
Preclinical and clinical data
There are relatively few data in rodent models evaluating the potential for sensitization in early life, yet this has not been identified as a general research need as have other health endpoints for early life exposures. This likely reflects the lower concern for sensitization in the neonatal period. Accordingly, most of the preclinical studies on early life exposure to skin allergens were conducted several decades ago. Consistent with what one would expect, Carter (1976) demonstrated that young mice (4.5 weeks old) sensitized with picryl chloride gave overall a significantly lower response (about 50%) upon challenge compared to mice that had achieved complete immunological competence, which is thought to occur at about 6 weeks of age in mice. To note, the OECD TG 429 for the LLNA specifies that the mice used for this predictive skin sensitization test should be between 8 and 12 weeks old to ensure complete immunological competence (OECD, 2010) .
There are also relatively few data in humans evaluating the potential for infants to mount an immune response. As early as 1960, Warwick et al. demonstrated that newborn infants (from 1.5 h to one month old) were not only unable to express a delayed allergy response, but were also unable to accept the passive transfer of maternal delayed hypersensitivity. Consistent with this, Epstein (1961) evaluated the frequency of contact sensitization to a Rhus (poison ivy) allergen, pentadecyl catechol, in 102 infants and children from one month to eight years of age. While children three to eight years old were readily sensitized and had reactions (rate and degree of severity) comparable to adults, infants less than one year old had a significantly diminished response: the incidence of positive reactions to rhus extract was 76% (28/37) for children ages 3-8, 50% (12/24) for children ages 1-3, and 30% (8/27) for infants under one year old. The incidence of more severe reactions was also higher in older children (38%) and lowest in infants under one year old (8.5%). Epstein suggested that: "these observations suggest that the mechanism of delayed hypersensitivity matures more slowly than other processes of immunity and resistance". Cassimos et al. (1980) studied the reactivity of infants to the industrial allergen 2,4-dinitrochlorobenzene (DNCB) compared to adults. A total of 284 infants ranging from newborns up to nine months old were evaluated. Over 90% of infants nine months old were found to react to DNCB; progressively lower reaction rates were found in younger infants: 88.5% in 7-month-old infants, 81.5% in 5-month-old infants, 76.7% in 4-month-old infants, 62.9% in 3-month old infants, 33.3% in 2-month-old infants, 25.7% in infants 2-4 weeks old, and only 6.8% in the first 15 days of life. This diminished response in early life is likely reflective of a reduced capacity for cell-mediated immunity. Age dependent delayed hypersensitivity responses were studied also by Franz et al. (1976) and Munoz and Limbert (1977) . They observed responses towards Candida albicans and streptokinase antigens or Candida and Diphteria tetanus toxin antigens and showed an increase of response with age of infants from (newborns) to children (up to 5 years or adulthood).
Only one study of premature infants was found in the literature (Uhr et al., 1960) . In that study premature infants (average birth weight of 1255 g), neonatal infants and infants between 2 and 12 months were sensitized percutaneously with Dinitrofluorobenzene (DNFB). Sensitization was induced in all older infants, and in 2/5 neonatal infants and 3/10 premature infants. Although a small number of infants were included, this study supports the hypothesis that the potential of a premature infant to mount an immune response will be even lower than that of a full-term infant (Melville and Moss, 2013) . In addition, the positive reactions elicited in the premature infants were less intense compared to those in older infants.
Summary and conclusions
Allergic contact dermatitis is a common skin condition that can affect a significant fraction of the general population in both adults and children of all ages. The QRA approach used in the conduct of skin safety assessments (e.g., for personal care products) incorporates a default 10-fold safety assessment factor to account for human heterogeneity, similar to quantitative methods for other systemic health endpoints. This does not refer to potential differences in exposure which need to be addressed separately for each individual case, as it is also accounted for in systemic toxicity risk assessment. ACD can occur in all stages of life, independent of age, but the primary causative allergens might differ between age groups. This seems to be attributed to differences in exposure throughout life, as well as non-standardized diagnostic patch testing approaches for children. This paper summarizes the available data and lines of evidence which support the generally accepted premise that children and infants are not expected to be more sensitive to the induction of contact allergy than adults. In fact, while children and older infants (e.g., > 6-7 months) appear to have a susceptibility comparable to that of adults, younger infants appear to be less susceptible based on the immaturity of the immune system at birth. This is supported by literature on infant responses to vaccines and more limited data on reactions to allergens. Although the data from Cassimos et al. (1980) suggest that infants < 2-4 months old are clearly less susceptible to the induction of ACD by DNCB, a specific definition for 'young infants' is not needed for this analysis because we only conclude that the current 10-fold SAF for inter-individual differences is fully inclusive of infants in general. Thus, while it remains prudent for all age groups to avoid contact with sensitizers, it is concluded that the quantitative methods used in safety evaluation to prevent the induction of skin sensitization are protective for infants, including neonates and premature infants.
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